-
A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the Efficacy of Guselkumab in Subjects with Familial Adenomatous Polyposis
Scottsdale/Phoenix, AZ; Jacksonville, FL
This is a proof-of-concept study to evaluate the preliminary clinical activity of guselkumab in subjects with Familial Adenomatous Polyposis. The study is designed to determine if guselkumab has clinical activity in the colorectum and duodenum, by reducing the number of polyps over a period of 24 weeks.
-
Clinical Trial to Evaluate the PrevisEA Device for Predicting Gastrointestinal Impairment
Rochester, MN
The purpose of this research is to study the performance of a device called PrevisEA, an investigational device not approved by the Food and Drug Administration (FDA). This research is sponsored by the maker of the PrevisEA device, Entac Medical Inc. This device listens to and records abdominal sounds which provides data that can help predict gastrointestinal impairment (GII). GII is a condition that is defined as the failure of oral re-feeding after abdominal surgery.
-
Post-Surgical Based Efforts to Reduce Preventable Readmissions and Optimize Length of Stay
Rochester, MN
The investigators believe that the lessons learned from studies regarding 30-day and 90-day readmission are primarily due to failure of early symptom recognition, and medical error. Through the aid of remote monitoring and early symptom detection, the hypothesis for the current proposal is that interventions can be recommended in an earlier, remote fashion that may result in earlier post-surgical discharge, prevent decompensation, and prevent increased readmissions that have been associated with decreased LOS in other surgical populations.